Nirvana Life Sciences Inc.

CNSX:NIRV Stock Report

Market Cap: CA$3.6m

Nirvana Life Sciences Past Earnings Performance

Past criteria checks 0/6

Nirvana Life Sciences's earnings have been declining at an average annual rate of -0.04%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually.

Key information

-0.04%

Earnings growth rate

0.4%

EPS growth rate

Pharmaceuticals Industry Growth23.1%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Jan 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Nirvana Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:NIRV Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Jan 240-110
31 Oct 230-110
31 Jul 230-210
30 Apr 230-110
31 Jan 230-610
31 Oct 220-610
31 Jul 220-610
30 Apr 220-610
31 Jan 220-100
31 Oct 210-100

Quality Earnings: NIRV is currently unprofitable.

Growing Profit Margin: NIRV is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NIRV's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare NIRV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NIRV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-47.5%).


Return on Equity

High ROE: NIRV's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies